Inhibition of miR‐34a‐5p can correct the p53‐DAPK axis disruption by upregulating DAPK protein and may have potential to be used as a therapeutic target to improve outcomes for ccRCC patients. This evidence concerns the gene TP53 and nonpapillary renal cell carcinoma.